OncoCyte Co. (NASDAQ:OCX - Get Free Report) major shareholder Broadwood Partners, L.P. bought 1,315,339 shares of the business's stock in a transaction on Wednesday, October 2nd. The shares were acquired at an average price of $2.95 per share, for a total transaction of $3,880,250.05. Following the completion of the purchase, the insider now owns 6,244,405 shares in the company, valued at approximately $18,420,994.75. The trade was a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Large shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.
OncoCyte Stock Performance
OCX stock opened at $2.89 on Monday. OncoCyte Co. has a 1 year low of $2.08 and a 1 year high of $4.34. The stock's fifty day moving average price is $3.07 and its 200-day moving average price is $2.93.
OncoCyte (NASDAQ:OCX - Get Free Report) last announced its earnings results on Thursday, August 8th. The company reported ($0.36) earnings per share (EPS) for the quarter. The firm had revenue of $0.10 million during the quarter. OncoCyte had a negative return on equity of 149.88% and a negative net margin of 3,558.46%.
Wall Street Analyst Weigh In
Watch this before it gets removed
From Porter & Company | Ad
If you missed it, my emergency election broadcast is now available - but will be removed soon
Click here to watch it now.
Several equities research analysts recently commented on the company. Needham & Company LLC reaffirmed a "buy" rating and set a $4.25 price objective on shares of OncoCyte in a research report on Friday, August 9th. StockNews.com started coverage on shares of OncoCyte in a report on Thursday. They set a "sell" rating on the stock. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $4.06.
Check Out Our Latest Report on OCX
About OncoCyte
(
Get Free Report)
OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
